Microhomology-mediated end joining drives complex rearrangements and over expression of MYC and PVT1 in multiple myeloma


Disclosures: Celgene Corporation: Employment, Equity Ownership: KM, MT, AT. Funding for data processing and storage was provided by Celgene Corporation. Other authors declare no competing interests.

Contributions: AM, CA, FED, GJM and BAW conceived and designed the study; AM, CA, PQ, AR, AH and AT collected clinical data, sequencing data and performed statistical testing; JK, DA and AT were responsible for collection and availability of CoMMpass study related data; JAD, KRR, SY and FED developed and maintained mouse models; RGT, SD and ET processed the samples and performed laboratory protocols; AM, CA, ET, JK, DA, GHJ, GJM and BAW analyzed and interpreted data; CA, MAB, CPW, KM and MT performed the bioinformatics of the sequencing data; All authors discussed the results, wrote, reviewed and approved the manuscript.